Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.

Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.

Abstract: The present invention provides compounds of formula I or II: wherein X1, X3, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.

Abstract: The present invention relates to compounds and pharmaceutically acceptable salts or solvates thereof for use in the treatment or prevention of fascioliasis. Some of these compounds are novel per se and also have activity as inhibitors of Schistosoma growth. The invention also relates to pharmaceutical compositions comprising such novel compounds, salts or solvates and to the use of such novel compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.

Abstract: The invention relates to compounds of Formula (I): and related aspects.

Abstract: The invention provides a compound of formula (I), or pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, wherein R1 is an optionally substituted phenyl, or an optionally substituted 5- or 6-membered aromatic heterocycle; and R2 is an optionally substituted 5- or 6-membered aromatic heterocycle. Also provided are pharmaceutical compositions comprising a compound of formula (I).

Abstract: The present invention provides compounds of formula I or II: wherein X1, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.

Abstract: The invention provides a compound of formula (I), or pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, wherein R1 is an optionally substituted phenyl, or an optionally substituted 5- or 6-membered aromatic heterocycle; and R2 is an optionally substituted 5- or 6-membered aromatic heterocycle. Also provided are pharmaceutical compositions comprising a compound of formula (I).

Abstract: A LIDAR device, including a housing, and an emitter device that is situated rotatably about a rotation axis and that is designed in such a way that the measuring beams of the emitter device intersect in the area of an exit aperture of the LIDAR device.

Abstract: The present invention provides compounds of formula I or II: wherein X1, X3, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.

Abstract: The present invention provides compounds of formula I wherein X1, X2, X3, X4, R1, R1a, R1b, R2?, R2?, R3?, R3?, R6 and R7 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.

Abstract: Unified automation of application development and delivery is provided. An automation pipeline execution coordinator may define a pipeline specification that includes actions to be performed, a triggering event definition and specification for determining execution context. The coordinator may concurrently detect triggering events for multiple pipelines matching the pipeline specification, and responsive to the detecting, determine execution contexts for the pipelines. The coordinator may then execute the multiple pipelines, where execution may proceed independently for pipelines with differing execution contexts. For pipelines sharing an execution context, execution of various actions of the respective pipelines may be coordinated. Execution context may be determined according to the specification for determining execution context, which may include an overridable default specification that determines context by locations of source data related to the triggering event.

Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.

Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).

Abstract: A method for generating light pulses of a LIDAR system. The method includes the following steps: a) generating a light pulse sequence, including at least one first light pulse and one second light pulse of different intensities by a light source, in particular a laser; b) emitting the light pulse sequence by the LIDAR system; c) receiving, by the LIDAR system, a portion of the light pulse sequence reflected by an object; d) evaluating the received portion of the light pulse sequence for measuring distance. A corresponding LIDAR system, a computer program and a machine-readable memory medium are also described.

Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.

Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).

Abstract: The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.

Abstract: The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.

Abstract: A lidar system having interference source detection, in particular, for a vehicle. An emitter unit and a detector unit are provided, so that reflected light for sampling a surrounding area may be detected. The light emitted by the emitter unit travels through a window out of the housing, and the light reflected by the surrounding area travels through the window into the housing. At least one secondary detector is provided, which is attached to a coupling-out surface of the window. The secondary detector is configured to detect scattered light propagating inside of the window. The lidar system includes a control unit, which is configured to evaluate scattered light detected by the at least one secondary detector, in order to detect interference sources on or in the window.